Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Antimicrobial Resistance in Patients with COVID-19: A Systematic Review and Meta-Analysis
68 Pages Posted: 3 May 2022
More...Abstract
Background: Frequent use of antibiotics in patients with COVID-19 threatens to fuel the public health threat of antimicrobial resistance (AMR). This study sought to determine the prevalence and predictors of bacterial infections and AMR in patients with COVID-19.
Methods: We performed a systematic review of studies evaluating bacterial co-infections (≤48 hours of presentation) and secondary infections (>48 hours after presentation) in outpatients or hospitalised patients with COVID-19. A search strategy using bacterial infection terms was applied to the World Health Organization COVID-19 Research Database on December 1, 2021. Studies reporting on microbiologically-confirmed bacterial infection in any anatomical site were eligible for inclusion. We reported the pooled prevalence of bacterial infections and AMR, by conducting a random-effects meta-analysis.
Findings: 148 studies evaluating 362 976 patients were included. The prevalence of bacterial co-infection in COVID-19 patients was 5·3% (95%CI: 3·8–7·4%), whereas prevalence of secondary bacterial infection was 18·4% (95%CI: 14·0 –23·7%). While 93 (63%) studies reported resistance or susceptibility data for at least one species, 42 (28%) reported comprehensive data on the prevalence of AMR. Of patients with documented bacterial infections, 60·8% (95%CI: 38·6 to 79·3%, 17 studies) were infected with resistant pathogens and 37.5% (95%CI: 26·9 to 49·5%, 42 studies) of the organisms were resistant. Significant study-level predictors for AMR included ICU setting, use of IL-6 inhibitors, diabetes, antibiotic use and geographical region (Eastern Mediterranean and Asia).
Interpretation: While the prevalence of bacterial co-infections in patients with COVID-19 is low, bacterial secondary infections are more frequent. Although infrequently evaluated, antibiotic resistance is highly prevalent in patients with COVID-19 who develop bacterial infections. These data can help to inform guidelines on appropriate antibiotic use in patients with COVID-19. Future research and surveillance evaluating the impact of COVID-19 on antibiotic resistance at the patient and population level are urgently needed.
Funding: World Health Organization
Declaration of Interest: The authors have no conflicts of interest to declare.
Keywords: COVID-19, antimicrobial resistance, antimicrobial stewardship
Suggested Citation: Suggested Citation